Peter C M van de Kerkhof: Influence Statistics

Peter C M van de Kerkhof

Peter C M van de Kerkhof

Department of Dermatology, Radboud University Medical Center, Nijmegan, Netherlands | Department of Dermatology, Radboud Institute for Health Sciences, Nijmegen, the ...

Peter C M van de: Expert Impact

Concepts for which Peter C M van de has direct influence: Skin diseases , Patients psoriasis , Scalp psoriasis , Calcipotriol ointment , Psoriasis patients , Epidermal proliferation , Plaque psoriasis .

Peter C M van de: KOL impact

Concepts related to the work of other authors for which for which Peter C M van de has influence: Psoriatic arthritis , Patients psoriasis , Atopic dermatitis , Skin diseases , Quality life , Photodynamic therapy , Monoclonal antibodies .

KOL Resume for Peter C M van de Kerkhof

Year
2022

Department of Dermatology, Radboud University Medical Center, Nijmegan, Netherlands

2021

Department of Dermatology, Radboud Institute for Health Sciences, Nijmegen, the Netherlands.

2020

Department of Dermatology, Radboud University Medical Center, Nijmegen, the Netherlands

2019

Radboud University Medical Center, Nijmegen, The Netherlands

2018

Department of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlands, View further author information

2017

Radboud Institute for Molecular Life Sciences (RIMLS), and, Radboud Institute for Health Sciences (RIHS), Nijmegen, Philips Research Eindhoven, Philips Electronics Nederland B.V., Eindhoven, and, RiverD International B.V., Rotterdam, The Netherlands

2016

Afdeling Dermatologie, Radboudumc, Huispostnummer 374, Postbus 9101, 6500 HB, Nijmegen, Nederland

Health, Medical and Neuropsychology Unit, Institute of Psychology, Leiden University, Leiden, Departments of, Medical Psychology, Dermatology and, Health Evidence, Radboud university medical center, and, Department of Dermatology, Canisius-Wilhelmina Hospital, Nijmegen, Department of Dermatology, Rijnstate Hospital, Velp, and, Department of Dermatology, Ziekenhuisgroep Twente, Almelo, The Netherlands

Department of Dermatology, Radboud university medical center

2015

Radboud University Medical Center, Department of Dermatology, Nijmegen, The Netherlands

2014

Dept of Dermatology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

2013

Department of Dermatology, Radboud University Medical Centre, Nijmegen, The Netherlands

2012

Dermatology Department, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

2011

Departments of Dermatology.

Department of Dermatology, Radboud University Nijmegen Medical Centre, 6525 GL Nijmegen, the Netherlands

2010

Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.

University Hospital Nijmegen, Nijmegen, the Netherlands (P.K.)

Departments of Dermatology

2009

Dermatologikum, Hamburg, Germany;, University Hospital Sint-Rafaël, Leuven, Belgium;, University Hospital, Nijmegen, and, Wyeth Research, Hoofddorp, The Netherlands;, Wyeth Research, Paris, France;, Wyeth Research, Collegeville, Pa., USA

Department of Dermatology, 370 Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, the Netherlands

2008

Department of Dermatology, UMC St Radboud, PO Box 9101, 65 HB Nijmegen, the Netherlands

2007

Department of Dermatology, Radboud University Nijmegen Medical Centre, Nijmegen Centre for Molecular Life Sciences, 652 GA, Nijmegen, The Netherlands

2006

Department of Dermatology, Radboud University Nijmegen, Medical Center, Nijmegen, The Netherlands

2005

Department of Dermatology, Radboud University Nijmegen Medical Centre, GL Nijmegen, The Netherlands

2004

From the Department of Dermatology, University Medical Center Nijmegen The Netherlands

2003

Departments of Dermatology and

From Waterlooa; University of Western Ontariob; Virga Jesse Ziekenhuis, Hasseltc; Bispebjerg Hospital, Copenhagend; University Hospital Kuopioe; Hopital Saint Eloi, Montpellierf; Klinikum der Goethe-Universität, Frankfurtg; Hume St Hospital, Dublinh; Kliniek voor Huidziekten, Nijmegeni; Sentralsjukehuset i Møre og Romsdal, Ålesundj; Universital Hospital, Lundk; Dermatologische Klinik Universitätsspital Zürichl; Leo Pharmaceuticalsm; Hammersmith Hospital, London.n

Prominent publications by Peter C M van de Kerkhof

KOL-Index: 28325 . BACKGROUND: Ixekizumab is a humanised monoclonal antibody against the proinflammatory cytokine interleukin 17A. We report two studies of ixekizumab compared with placebo or etanercept to assess the safety and efficacy of specifically targeting interleukin 17A in patients with widespread moderate-to-severe psoriasis. METHODS: In two prospective, double-blind, multicentre, phase 3 studies ...
Known for Placebo Etanercept | Patients Ixekizumab | 2 Weeks | Nonsteroidal Antibodies
KOL-Index: 24855 . BACKGROUND: New therapeutic options are needed for patients with psoriasis. Tofacitinib, an oral Janus kinase inhibitor, is being investigated as a treatment for moderate-to-severe chronic plaque psoriasis. In this study, we aimed to compare two tofacitinib doses with high-dose etanercept or placebo in this patient population. METHODS: In this phase 3, randomised, multicentre, ...
Known for Tofacitinib Etanercept | Placebo Patients | Chronic Plaque | Phase 3
KOL-Index: 18714 . BACKGROUND: T-cell infiltration in plaque psoriasis has recently been an important subject of investigation. Interestingly, comparative analyses of the disease-specific composition of the lesional T-cell infiltrate in plaque psoriasis and other inflammatory dermatoses have only sparsely been performed. OBJECTIVES: To compare plaque psoriasis vs. atopic dermatitis and lichen ruber planus ...
Known for Lichen Planus | Atopic Dermatitis | Plaque Psoriasis | Epidermal Proliferation
KOL-Index: 17595 . BACKGROUND: Knowledge about quality of life and sexual health in patients with genital psoriasis is limited. OBJECTIVES: We studied quality of life and sexual function in a large group of patients with genital psoriasis by means of validated questionnaires. In addition, we evaluated whether sufficient attention is given by healthcare professionals to sexual problems in patients with ...
Known for Sexual Health | Genital Psoriasis | Quality Life | Psychological Surveys
KOL-Index: 17224 . BACKGROUND: Knowledge on the sequential treatment of psoriasis with biologics with regard to efficacy and safety is sparse. This also applies to the efficacy and safety of adalimumab in patients previously treated with etanercept. The relationship between the reasons for discontinuation of etanercept and the response to adalimumab is not clear in psoriasis. OBJECTIVES: To evaluate the ...
Known for Patients Psoriasis | Secondary Failure | Etanercept Adalimumab | Monoclonal Antibodies
KOL-Index: 16071 . BACKGROUND: Physical symptoms of skin diseases have been shown to negatively affect patients' wellbeing. Although insight into physical symptoms accompanying skin diseases is relevant for the management and treatment of skin diseases, the prevalence of physical symptoms among patients with skin diseases is a rather unexplored territory. OBJECTIVES: The goal of the present study was to ...
Known for Skin Diseases | Physical Symptoms | Fatigue Patients | Itch Pain
KOL-Index: 16003 . BACKGROUND: In previous studies, etanercept 25 mg twice weekly (BIW) or 50 mg BIW significantly reduced disease severity in patients with plaque psoriasis and demonstrated a favourable safety profile. OBJECTIVES: To assess the efficacy and safety of etanercept 50 mg administered once weekly (QW) compared with placebo in patients with moderate-to-severe plaque psoriasis over 24 ...
Known for Etanercept 50 | Plaque Psoriasis | Week Patients | Placebo Qw
KOL-Index: 15959 . Physical complaints, such as pain, can be effectively reduced by placebo effects through induction of positive expectations, or increased by nocebo effects through induction of negative expectations. In the present study, verbally induced nocebo and placebo effects on itch were experimentally investigated for the first time. In part 1, the role of verbal suggestions in inducing nocebo ...
Known for Verbal Suggestions | Placebo Effects | Itch Pain | Histamine Application
KOL-Index: 15403 . BACKGROUND: Biologic agents offer a range of new therapeutic options for patients with psoriasis; however, the relative benefit-risk profiles of such therapies are not well known. We compared two biologic agents, ustekinumab (an interleukin-12 and interleukin-23 blocker) and etanercept (an inhibitor of tumor necrosis factor alpha), for the treatment of psoriasis. METHODS: We randomly ...
Known for Ustekinumab Etanercept | Pasi Week | 75 Improvement | Patients Psoriasis
KOL-Index: 14290 . BACKGROUND: Chronic skin diseases, such as atopic dermatitis and psoriasis, are known to affect quality of life by heightening psychological distress. Knowledge about factors contributing to psychological distress is essential for supporting physicians in diagnostic and multidisciplinary treatment options for patients psychologically at risk. OBJECTIVES: To examine whether generic ...
Known for Psychological Distress | Atopic Dermatitis | Chronic Skin Diseases | Patients Psoriasis
KOL-Index: 13598 . BACKGROUND: Methotrexate (MTX) use is associated with hepatic fibrosis in psoriasis patients. To monitor this serial liver biopsies were performed. The Fibroscan and the Fibrotest are two novel, non-invasive methods that might be able to assess MTX-induced hepatic fibrosis. AIM: Evaluating the accuracy and feasibility of the Fibroscan and Fibrotest to detect significant MTX-induced liver ...
Known for Psoriasis Patients | Liver Fibrosis | Fibroscan Fibrotest | Methotrexate Mtx
KOL-Index: 13328 . The therapeutic efficacy and tolerability of calcipotriol ointment and betamethasone valerate ointment in psoriasis were compared in a multicentre, prospective, randomised, double-blind, right/left trial. 345 inpatients and outpatients with psoriasis vulgaris of symmetrical distribution were treated twice daily for 6 weeks with calcipotriol ointment 50 micrograms/g and betamethasone ...
Known for Betamethasone Valerate | Psoriasis Vulgaris | 6 Weeks | Calcipotriol Ointment
KOL-Index: 13000 . BACKGROUND: Calcipotriol and betamethasone dipropionate are both widely used, effective treatments for psoriasis. Vitamin D analogues and topical corticosteroids have different mechanisms of action in the treatment of psoriasis. A new vehicle has been developed in order to contain both calcipotriol (50 micro g g-1) and betamethasone dipropionate (0.5 mg g-1) in an ointment form. By using ...
Known for Psoriasis Vulgaris | Efficacy Safety | Daily Calcipotriol | Betamethasone Dipropionate
KOL-Index: 12993 . The structure and function of the tumor microvasculature is of great interest for cancer biology, diagnosis, and therapy. The distribution of endothelial cells, pericytes, and basal lamina in tumors is not well documented. In this study, the authors investigated the distribution of markers for these different components in a series of malignant human tumors and in human granulation tissue, ...
Known for Granulation Tissue | Endothelial Cells | Differential Expression | Basal Lamina
KOL-Index: 12833 . Placebo and nocebo effects are known to play a key role in treatment effects in a wide variety of conditions. These effects have frequently been investigated with regard to pain and also in other physical sensations, but have hardly been investigated with regard to itch. In addition, neither in pain nor in any other physical sensation, the single and combined contribution of the expectancy ...
Known for Verbal Suggestion | Nocebo Effects | Pain Itch | Physical Sensations

Key People For Skin Diseases

Top KOLs in the world
#1
Christopher Ernest Maitland Griffiths
patients psoriasis retinoic acid human skin
#2
Roderick James Hay
global burden skin disease tinea capitis
#3
Hywel C G Williams
atopic eczema cochrane skin basal cell carcinoma
#4
David Joel Margolis
atopic dermatitis united states pressure ulcers
#5
Donald Y M Leung
atopic dermatitis eczema herpeticum food allergy
#6
John J Voorhees
human skin retinoic acid ultraviolet irradiation

Department of Dermatology, Radboud University Medical Center, Nijmegan, Netherlands | Department of Dermatology, Radboud Institute for Health Sciences, Nijmegen, the Netherlands. | Department of Dermatology, Radboud University Medical Center, Nijmege